MX365245B - Inhibidores de glucosilceramida sintasa. - Google Patents

Inhibidores de glucosilceramida sintasa.

Info

Publication number
MX365245B
MX365245B MX2013010710A MX2013010710A MX365245B MX 365245 B MX365245 B MX 365245B MX 2013010710 A MX2013010710 A MX 2013010710A MX 2013010710 A MX2013010710 A MX 2013010710A MX 365245 B MX365245 B MX 365245B
Authority
MX
Mexico
Prior art keywords
glucosylceramide synthase
synthase inhibitors
treatment
inhibitors
glucosylceramide
Prior art date
Application number
MX2013010710A
Other languages
English (en)
Other versions
MX2013010710A (es
Inventor
Bourque Elyse
Celatka Cassandra
Hirth Bradford
Metz Markus
Zhao Zhong
Skerlj Renato
Xiang Yibin
Jancisics Katherine
Marshall John
Cheng Seng
Scheule Ronald
Cabrera-Salazar Mario
Good Andrew
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of MX2013010710A publication Critical patent/MX2013010710A/es
Publication of MX365245B publication Critical patent/MX365245B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D455/00—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
    • C07D455/02—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing not further condensed quinolizine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01022—Alpha-galactosidase (3.2.1.22)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)

Abstract

La invención está relacionada con inhibidores de glucosilceramida sintasa (GCS) útiles para el tratamiento de enfermedades metabólicas, tales como enfermedades de almacenamiento lisosómico, solos o en combinación con terapia de remplazo enzimático, y para el tratamiento de cáncer.
MX2013010710A 2011-03-18 2012-03-16 Inhibidores de glucosilceramida sintasa. MX365245B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161454034P 2011-03-18 2011-03-18
US201261590711P 2012-01-25 2012-01-25
PCT/US2012/029417 WO2012129084A2 (en) 2011-03-18 2012-03-16 Glucosylceramide synthase inhibitors

Publications (2)

Publication Number Publication Date
MX2013010710A MX2013010710A (es) 2013-10-17
MX365245B true MX365245B (es) 2019-05-28

Family

ID=46879977

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2018007961A MX368340B (es) 2011-03-18 2012-03-16 Inhibidores de glucosilceramida sintasa.
MX2013010710A MX365245B (es) 2011-03-18 2012-03-16 Inhibidores de glucosilceramida sintasa.
MX2019008428A MX2019008428A (es) 2011-03-18 2013-09-18 Inhibidores de glucosilceramida sintasa.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2018007961A MX368340B (es) 2011-03-18 2012-03-16 Inhibidores de glucosilceramida sintasa.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2019008428A MX2019008428A (es) 2011-03-18 2013-09-18 Inhibidores de glucosilceramida sintasa.

Country Status (36)

Country Link
US (5) US9139580B2 (es)
EP (2) EP3673906A1 (es)
JP (2) JP6117708B2 (es)
KR (1) KR101987736B1 (es)
CN (2) CN103917094B (es)
AR (1) AR085425A1 (es)
AU (2) AU2012231275A1 (es)
BR (2) BR112013023774B1 (es)
CA (1) CA2830540C (es)
CL (1) CL2013002688A1 (es)
CO (1) CO6801749A2 (es)
CR (1) CR20190034A (es)
DK (1) DK2685986T3 (es)
DO (1) DOP2013000209A (es)
EC (1) ECSP13012978A (es)
ES (1) ES2774293T3 (es)
GT (1) GT201300215A (es)
HR (1) HRP20200226T1 (es)
HU (1) HUE047888T2 (es)
IL (1) IL228514B (es)
LT (1) LT2685986T (es)
MA (1) MA35023B1 (es)
MX (3) MX368340B (es)
MY (1) MY173998A (es)
NI (1) NI201300083A (es)
PE (1) PE20140412A1 (es)
PL (1) PL2685986T3 (es)
PT (1) PT2685986T (es)
RS (1) RS59963B1 (es)
RU (2) RU2018104472A (es)
SI (1) SI2685986T1 (es)
TW (2) TWI546301B (es)
UA (1) UA118248C2 (es)
UY (1) UY33958A (es)
WO (1) WO2012129084A2 (es)
ZA (1) ZA201307016B (es)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012231275A1 (en) * 2011-03-18 2013-10-17 Genzyme Corporation Glucosylceramide synthase inhibitors
MA37975B2 (fr) * 2012-09-11 2021-03-31 Genzyme Corp Inhibiteurs de synthase de glucosylcéramide
AU2019222801B2 (en) * 2012-09-11 2021-02-18 Genzyme Corporation Glucosylceramide synthase inhibitors
JO3713B1 (ar) * 2013-03-15 2021-01-31 Genzyme Corp أشكال ملح (s)-كوينوكليدين-3-يل(2-(2-(4-فلوروفينيل)ثيازول-4-يل)بروبان-2-يل)كارباميت
HUE064200T2 (hu) 2013-03-15 2024-02-28 Genzyme Corp Eljárás glukozilceramid szintáz inhibitorok elõállítására
CN104418851A (zh) * 2013-09-02 2015-03-18 上海龙翔生物医药开发有限公司 奎宁环衍生物的制备方法及纯化方法
PL3079695T3 (pl) * 2013-12-11 2021-09-27 Genzyme Corporation Inhibitory syntazy glukozyloceramidu
WO2015181837A2 (en) * 2014-05-30 2015-12-03 Sphaera Pharma Pvt. Ltd. Novel compounds as anti-tubercular agents
JP6749923B2 (ja) 2015-02-02 2020-09-02 ザ リージェンツ オブ ザ ユニバーシティー オブ ミシガン グルコシルセラミドシンターゼ阻害剤及びそれを使用した治療方法
TW201642855A (zh) * 2015-03-10 2016-12-16 健臻公司 用於治療蛋白質病變之方法
US9802942B2 (en) 2015-07-01 2017-10-31 Northwestern University Substituted 4-methyl-pyrrolo[1,2-A]pyrimidine-8-carboxamide compounds and uses thereof for modulating glucocerebrosidase activity
EP3317265A4 (en) 2015-07-01 2019-04-17 Northwestern University SUBSTITUTED CHINAZOLIN COMPOUNDS AND USES THEREOF FOR MODULATING GLUCOCEREBROSIDASE ACTIVITY
AR107483A1 (es) * 2016-01-29 2018-05-02 Hanmi Pharm Ind Co Ltd Conjugado de enzimas terapéuticas
US20200124624A1 (en) 2016-03-25 2020-04-23 The Brigham And Women`S Hospital, Inc. Biomarkers of proteopathies and uses thereof
EP3318277A1 (en) 2016-11-04 2018-05-09 Institut du Cerveau et de la Moelle Epiniere-ICM Inhibitors of glucosylceramide synthase for the treatment of motor neuron diseases
CA3043709A1 (en) 2016-11-14 2018-05-17 Berg Llc Methods for treating parkinson's disease
PL3562821T3 (pl) 2016-12-28 2021-06-14 Minoryx Therapeutics S.L. Związki izochinolinowe, sposoby ich wytwarzania i ich zastosowania terapeutyczne w stanach związanych ze zmianą aktywności beta-galaktozydaz
BR112019013571A2 (pt) 2016-12-29 2020-01-07 Minoryx Therapeutics S.L. Compostos heteroarila e seu uso
CN108341822B (zh) * 2017-01-23 2021-04-16 广州市恒诺康医药科技有限公司 Fxr受体调节剂及其制备方法和应用
US11498904B2 (en) * 2017-11-14 2022-11-15 Merck Sharp & Dohme Llc Substituted biaryl compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors
WO2019126776A1 (en) 2017-12-21 2019-06-27 Lysosomal Therapeutics Inc. Crystalline substituted cyclohexyl pyrazolo[1,5-a]pyrimidinyl carboxamide compound and therapeutic uses thereof
JP7317721B2 (ja) * 2018-01-31 2023-07-31 武田薬品工業株式会社 複素環化合物
US10519157B2 (en) * 2018-02-09 2019-12-31 X-Cutag Therapeutics, Inc. Deuterated compounds for treating Fabry, Gaucher, Parkinson's and related diseases and conditions, and compositions and methods thereof
KR102233530B1 (ko) * 2018-11-22 2021-03-31 (주)프로스테믹스 엑소좀 및 이의 다양한 용도
KR102342902B1 (ko) * 2018-11-22 2021-12-24 (주)프로스테믹스 엑소좀 및 이의 다양한 용도
KR102342901B1 (ko) * 2018-11-22 2021-12-24 (주)프로스테믹스 엑소좀 및 이의 다양한 용도
MX2021009383A (es) 2019-02-04 2021-09-10 Genzyme Corp Metodos para el tratamiento contra sintomas y trastornos asociados a enfermedades del almacenamiento lisosomico.
JP2022519131A (ja) 2019-02-04 2022-03-18 ジェンザイム・コーポレーション グルコシルセラミドシンターゼ（ｇｃｓ）阻害剤を使用した繊毛病の処置
WO2020193746A1 (en) 2019-03-28 2020-10-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the survival of patients suffering from melanoma
JP7539382B2 (ja) 2019-07-29 2024-08-23 武田薬品工業株式会社 複素環化合物
JP2022553107A (ja) 2019-10-23 2022-12-21 ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・ミシガン グルコシルセラミドシンターゼ阻害剤およびそれを使用する治療方法
ES2982711T3 (es) * 2019-11-15 2024-10-17 Yuhan Corp Derivados que tienen un resto 1,2,3,4-tetrahidronaftaleno o una sal farmacéuticamente aceptable de los mismos y composiciones farmacéuticas que comprenden los mismos
KR20210059632A (ko) * 2019-11-15 2021-05-25 주식회사유한양행 신규의 2,3-다이하이드로-1h-인덴 또는 2,3-다이하이드로벤조퓨란 모이어티를 갖는 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법, 및 이를 포함하는 약학 조성물
KR20220150880A (ko) 2019-11-25 2022-11-11 게인 테라퓨틱스 에스에이 아릴 및 헤테로아릴 화합물, 및 갈락토세레브로시다제의 활성 변경과 관련된 병태에서의 치료 용도
WO2021105908A1 (en) 2019-11-25 2021-06-03 Gain Therapeutics Sa Heteroaryl compounds and therapeutic uses thereof in conditions associated with the alteration of the activity of beta-glucocerebrosidase
EP4100009A1 (en) 2020-02-03 2022-12-14 Genzyme Corporation Methods for treating neurological symptoms associated with lysosomal storage diseases
WO2021156774A1 (en) 2020-02-03 2021-08-12 Gain Therapeutics Sa Combination therapy for treating mps1
WO2021214771A1 (en) 2020-04-23 2021-10-28 The Israel Institute of Biological Research (IIBR) Glucosylceramide synthase inhibitors for prevention and treatment of viral diseases
US20230212123A1 (en) 2020-04-28 2023-07-06 The Regents Of The University Of Michigan Pyridine Inhibitors of Glucosylceramide Synthase and Therapeutic Methods Using the Same
IL300090A (en) 2020-07-24 2023-03-01 Genzyme Corp Pharmaceutical preparations containing VENGLUSTAT
AU2022272851A1 (en) * 2021-05-11 2023-10-05 Green Cross Corporation Novel compounds having inhibitory activity against glucosylceramide synthase or pharmaceutically acceptable salt thereof, processes for preparing the same, and pharmaceutical compositions comprising the same
WO2023042177A1 (en) 2021-09-20 2023-03-23 Gt Gain Therapeutics Sa Enantiomers of 5-((7-chloroisoquinolin-1-yl)amino)-n-(6-methoxy-1,2,3,4-tetrahydronaphthalen-2-yl)picolinamide
WO2023239892A1 (en) * 2022-06-10 2023-12-14 Arkuda Therapeutics Compounds for modulation of cd68 and uses thereof
KR20240057364A (ko) * 2022-10-24 2024-05-02 주식회사유한양행 다이메틸-2,3-다이하이드로-1h-인덴 유도체의 신규 염 및 이의 제조방법
KR20240057365A (ko) * 2022-10-24 2024-05-02 주식회사유한양행 다이메틸-2,3-다이하이드로-1h-인덴 유도체의 개선된 제조방법
WO2024116127A1 (en) 2022-12-01 2024-06-06 Genzyme Corporation Venglustat in combination with a strong or moderate inhibitor of cyp3a4
WO2024141998A1 (en) 2022-12-30 2024-07-04 Gt Gain Therapeutics Sa Method of treating tauopathies
CN118496159B (zh) * 2024-07-18 2024-09-24 广州医科大学附属市八医院 一种化合物在制备具有预防和/或治疗肝纤维化作用的药物中的应用

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE640616A (es) 1962-12-19
US3492397A (en) 1967-04-07 1970-01-27 Warner Lambert Pharmaceutical Sustained release dosage in the pellet form and process thereof
US4060598A (en) 1967-06-28 1977-11-29 Boehringer Mannheim G.M.B.H. Tablets coated with aqueous resin dispersions
US3538214A (en) 1969-04-22 1970-11-03 Merck & Co Inc Controlled release medicinal tablets
US4173626A (en) 1978-12-11 1979-11-06 Merck & Co., Inc. Sustained release indomethacin
WO1988002477A1 (en) * 1986-10-03 1988-04-07 Micro Motion, Inc. Density insensitive coriolis mass flow rate meter
AU611976B2 (en) 1987-12-24 1991-06-27 John Wyeth & Brother Limited Aroyl urea and carbamic acid derivatives of azabicyclo compounds
US5549892A (en) 1988-12-23 1996-08-27 Genzyme Corporation Enhanced in vivo uptake of glucocerebrosidase
US5236838A (en) 1988-12-23 1993-08-17 Genzyme Corporation Enzymatically active recombinant glucocerebrosidase
IT1228293B (it) * 1989-02-06 1991-06-07 Angeli Inst Spa Benzoderivati di composti eterociclici contenenti azoto.
US5272071A (en) 1989-12-22 1993-12-21 Applied Research Systems Ars Holding N.V. Method for the modification of the expression characteristics of an endogenous gene of a given cell line
US5968502A (en) 1991-11-05 1999-10-19 Transkaryotic Therapies, Inc. Protein production and protein delivery
KR970701174A (ko) * 1994-02-10 1997-03-17 오노다 마사요시 신규한 카바메이트 유도체 및 이의 의약 조성물(Novel carbamate derivative and medicinal composition containing the same)
JPH08198751A (ja) * 1995-01-19 1996-08-06 Yamanouchi Pharmaceut Co Ltd カルバメート誘導体
JP2000500139A (ja) * 1995-11-08 2000-01-11 アメリカン・ホーム・プロダクツ・コーポレイション １−アザビシクロヘプタン誘導体およびそれらの医薬用途
EP1027069B1 (en) 1997-10-29 2006-07-26 Genzyme Corporation Gene therapy for gaucher disease
US6953855B2 (en) * 1998-12-11 2005-10-11 Targacept, Inc. 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof
FR2791678B1 (fr) * 1999-03-30 2001-05-04 Synthelabo Derives de 1,4-diazabicyclo [3.2.2] nonane-4-carboxylates et -carboxamides, leur preparation et leur application en therapeutique
GB0010955D0 (en) * 2000-05-05 2000-06-28 Novartis Ag Organic compounds
CZ301323B6 (cs) * 2000-12-22 2010-01-13 Laboratorios Almirall, S.A. Chinuklidinkarbamátové deriváty a lécivé kompozice je obsahující
ATE348829T1 (de) * 2001-02-06 2007-01-15 Pfizer Prod Inc Pharmazeutische zusammensetzungen zur behandlung von störungen des zns oder anderen erkrankungen
JP2003267977A (ja) * 2002-03-14 2003-09-25 Yamanouchi Pharmaceut Co Ltd キヌクリジン誘導体
ES2203327B1 (es) * 2002-06-21 2005-06-16 Almirall Prodesfarma, S.A. Nuevos carbamatos de quinuclidina y composiciones farmaceuticas que los contienen.
CA2492404C (en) * 2002-07-17 2012-02-07 Oxford Glycosciences (Uk) Ltd Piperidinetriol derivatives as inhibitors of glycosylceramide synthase
AU2003248122A1 (en) * 2002-07-25 2004-02-16 Kotobuki Pharmaceutical Co., Ltd. Sodium channel inhibitor
SE0202598D0 (sv) * 2002-09-02 2002-09-02 Astrazeneca Ab Alpha-7 Nicotinic receptor agonists and statins in combination
PT1949901E (pt) * 2002-12-06 2014-05-23 The Feinstein Inst Medical Res Método para a determinação de um agonista colinérgico selectivo para um receptor nicotínico alfa 7
GB0400812D0 (en) 2004-01-14 2004-02-18 Celltech R&D Ltd Novel compounds
JP2007186422A (ja) * 2004-01-28 2007-07-26 Astellas Pharma Inc アリールスルフィド誘導体
JP2008504282A (ja) * 2004-06-23 2008-02-14 ザ ファインスタイン インスティテュート フォー メディカル リサーチ コリンレセプターの薬理活性により腸閉塞を処置する方法
JP2008519840A (ja) 2004-11-10 2008-06-12 ジェンザイム・コーポレイション 糖尿病の処置方法
EP1976519A2 (en) * 2006-01-27 2008-10-08 Yale University Cytisine and acetylcholine analogs and methods of treating mood disorders
US7840109B2 (en) * 2006-08-14 2010-11-23 Adc Telecommunications, Inc. Factory spliced cable assembly
US8252789B2 (en) * 2007-11-29 2012-08-28 Neuraltus Pharmaceuticals, Inc. Compositions and methods for treating lysosomal disorders
WO2010014554A1 (en) * 2008-07-28 2010-02-04 Genzyme Corporation Glucosylceramide synthase inhibition for the treatment of collapsing glomerulopathy and other glomerular disease
WO2010015816A2 (en) * 2008-08-06 2010-02-11 Summit Corporation Plc Treatment of lysosomal storage disorders and other proteostatic diseases
EP2154136A1 (en) * 2008-08-08 2010-02-17 CHIESI FARMACEUTICI S.p.A. Quinuclidine carbonate derivatives and medicinal compositions thereof
WO2010091164A1 (en) * 2009-02-06 2010-08-12 Exelixis, Inc. Inhibitors of glucosylceramide synthase
WO2010091104A1 (en) * 2009-02-06 2010-08-12 Exelixis, Inc. Glucosylceramide synthase inhibitors
US8771387B2 (en) * 2009-06-09 2014-07-08 Sundrop Fuels, Inc. Systems and methods for solar-thermal gasification of biomass
EP2470199B1 (en) 2009-08-28 2019-05-22 Icahn School of Medicine at Mount Sinai Dose escalation enzyme replacement therapy for treating acid sphingomyelinase deficiency
AU2012231275A1 (en) * 2011-03-18 2013-10-17 Genzyme Corporation Glucosylceramide synthase inhibitors

Also Published As

Publication number Publication date
DK2685986T3 (da) 2020-03-02
RU2018104472A3 (es) 2021-04-30
TWI634119B (zh) 2018-09-01
TW201716404A (zh) 2017-05-16
MX368340B (es) 2019-09-30
WO2012129084A2 (en) 2012-09-27
US9126993B2 (en) 2015-09-08
MX2013010710A (es) 2013-10-17
LT2685986T (lt) 2020-03-10
JP2014517808A (ja) 2014-07-24
IL228514B (en) 2019-09-26
HRP20200226T1 (hr) 2020-05-29
CO6801749A2 (es) 2013-11-29
PE20140412A1 (es) 2014-04-01
JP2017141255A (ja) 2017-08-17
HUE047888T2 (hu) 2020-05-28
MX2019008428A (es) 2019-10-30
MY173998A (en) 2020-03-03
AR085425A1 (es) 2013-10-02
AU2016244305B2 (en) 2018-05-24
RU2018104472A (ru) 2019-02-22
RU2645675C2 (ru) 2018-02-27
AU2016244305A1 (en) 2016-11-03
IL228514A0 (en) 2013-12-31
AU2012231275A1 (en) 2013-10-17
SI2685986T1 (sl) 2020-03-31
KR20140092239A (ko) 2014-07-23
RU2013146550A (ru) 2015-04-27
ECSP13012978A (es) 2015-04-30
BR112013023774B1 (pt) 2022-01-11
CA2830540C (en) 2021-04-27
UA118248C2 (uk) 2018-12-26
NI201300083A (es) 2014-02-28
DOP2013000209A (es) 2014-04-15
CL2013002688A1 (es) 2014-03-07
EP2685986A4 (en) 2015-03-04
US20160207933A1 (en) 2016-07-21
NZ615857A (en) 2016-08-26
JP6117708B2 (ja) 2017-04-19
PT2685986T (pt) 2020-03-05
UY33958A (es) 2012-10-31
TW201300383A (zh) 2013-01-01
GT201300215A (es) 2015-02-09
EP3673906A1 (en) 2020-07-01
CN103917094A (zh) 2014-07-09
US9139580B2 (en) 2015-09-22
ES2774293T3 (es) 2020-07-20
PL2685986T3 (pl) 2020-07-27
US20140255381A1 (en) 2014-09-11
EP2685986B1 (en) 2019-11-27
CN107080747B (zh) 2021-02-26
JP6420860B2 (ja) 2018-11-07
BR112013023774A2 (pt) 2016-12-06
ZA201307016B (en) 2014-05-28
WO2012129084A3 (en) 2014-04-24
EP2685986A2 (en) 2014-01-22
CN103917094B (zh) 2016-11-09
US20140371460A1 (en) 2014-12-18
CN107080747A (zh) 2017-08-22
TWI546301B (zh) 2016-08-21
MA35023B1 (fr) 2014-04-03
US20210261557A1 (en) 2021-08-26
KR101987736B1 (ko) 2019-06-11
CR20190034A (es) 2019-05-20
US20200048266A1 (en) 2020-02-13
CA2830540A1 (en) 2012-09-27
BR122019017719B1 (pt) 2022-08-23
RS59963B1 (sr) 2020-03-31

Similar Documents

Publication Publication Date Title
MX2019008428A (es) Inhibidores de glucosilceramida sintasa.
TN2015000091A1 (en) Glucosylceramide synthase inhibitors
SG10201804952QA (en) Glucosylceramide synthase inhibitors
TN2012000280A1 (en) Methods of administering pirfenidone therapy
MX365464B (es) Prodecimiento para preparar inhibidores de la glucosilceramida sintasa.
MX2013008212A (es) Derivados de 7-azaindol.
MX2016003486A (es) Inhibidores de glucosilceramida sintasa para el tratamiento de enfermedades.
MX356525B (es) Vectores de virus asociados con adeno (aav) para uso en terapia de genes de coroideremia.
TN2015000427A1 (en) Salt forms of (S)-Quinuclidin-3-yl (2-(2-(4-fluorophenyl)thiazol-4-yl)propan-2-yl)carbamate
MX2015001551A (es) Compuestos y composiciones activadoras de enzima.
MX2014010713A (es) Activacion de procaspasa 3 mediante terapia de combinacion.
IN2014DN08385A (es)
TN2013000368A1 (en) Glucosylceramide synthase inhibitors
UA59700U (ru) Способ лечения метаболического синдрома
UA112059C2 (uk) Комбінована терапія із кріохірургією і іміквімодом для лікування актинічного кератозу (варіанти)

Legal Events

Date Code Title Description
FG Grant or registration